Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease.

Autor:	Gómez-Sámano MÁ; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Vargas-Abonce VP; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Martínez-Sánchez FD; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Palacios-Báez L; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Vera-Zertuche JM; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Navarro-Flores MF; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Morales-García MG; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Fonseca-Correa JI; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Zuarth-Vázquez JM; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Vega-Vega O; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Correa-Rotter R; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Rincón-Pedrero R; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Morales-Buenrostro LE; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Alberú-Gómez J; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Ramírez-González JB; Department of Preventive Medicine and Public Health, Universidad Nacional Autónoma de México, Mexico City, Mexico., Pacheco-Domínguez RL; Department of Preventive Medicine and Public Health, Universidad Nacional Autónoma de México, Mexico City, Mexico., López-Cervantes M; Department of Preventive Medicine and Public Health, Universidad Nacional Autónoma de México, Mexico City, Mexico., Mendoza-de-la-Garza MLÁ; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Baeza-Arias YV; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Espinosa-Cuevas Á; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., López-Carrasco G; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., López-Estrada A; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Guillén-Pineda LE; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Gómez-Pérez FJ; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico., Cuevas-Ramos D; Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga # 15, Sección XVI Tlalpan 14000, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in endocrinology and metabolism [Ther Adv Endocrinol Metab] 2021 Mar 29; Vol. 12, pp. 20420188211001160. Date of Electronic Publication: 2021 Mar 29 (Print Publication: 2021).
DOI:	10.1177/20420188211001160
Abstrakt:	Background and Aims: Oxidative stress (OS) induces the production of fibroblast growth factor 21 (FGF21). Previous data have revealed that FGF21 protects cells from OS injury and death, making it a potential therapeutic option for many diseases with increased OS. However, the association of this growth factor with OS markers in humans with chronic kidney disease (CKD) remains unknown. This study aims to evaluate the association of serum FGF21 with serum total antioxidant capacity (TAC) and oxidized low-density lipoproteins (OxLDL) in subjects in different stages of kidney disease. Methods: This is a cross-sectional study that included 382 subjects with different stages of CKD, irrespective of type 2 diabetes (T2D) diagnosis. Associations of serum FGF21 with OxLDL, TAC, sex, age, body mass index (BMI), fasting plasma glucose, estimated glomerular filtration rate (eGFR), T2D, and smoking, were evaluated through bivariate and partial correlation analyses. Independent associations of these variables with serum FGF21 were evaluated using multiple linear regression analysis. Results: Serum FGF21 was significantly and positively correlated with age ( r  = 0.236), TAC (lnTAC) ( r  = 0.217), and negatively correlated with eGFR ( r  = -0.429) and male sex ( r  = -0.102). After controlling by age, sex, BMI, T2D, smoking, and eGFR; both TAC and OxLDL were positively correlated with FGF21 ( r  = 0.117 and 0.158 respectively, p  < 0.05). Using multiple linear regression analysis, eGFR, male sex, T2D, OxLDL, and TAC were independently associated with serum FGF21 (STDβ = -0.475, 0.162, -0.153, 0.142 and 0.136 respectively; p  < 0.05 for all) adjusted for age, BMI, smoking, and fasting plasma glucose. Conclusion: A positive association between serum FGF21 and OS has been found independently of renal function in humans. Results from the present study provide novel information for deeper understanding of the role of FGF21 in OS in humans with CKD and T2D; mechanistic studies to explain the association of serum FGF21 with oxidative stress in CKD are needed. Competing Interests: Conflict of interest statement: The authors declare that there is no conflict of interest. (© The Author(s), 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu